CHB


China Biotech Innovation ETF

Reasons to Consider CHB

High Growth Potential

CHB enables investors to access high growth potential through companies central to the development of biotechnology in China.

Targeted Exposure

CHB delivers targeted exposure to an emerging theme and industry.

ETF Efficiency

In a single trade, CHB delivers access to dozens of companies with high exposure to the biotech theme in China.

Key Information As of 01/19/22

Inception Date 09/22/20
Total Expense Ratio 0.67%
Net Assets $3.65 million
NAV $13.51
Fact Sheet

ETF Summary

The Global X China Biotech Innovation ETF (CHB) seeks to invest in companies that are directly involved in China’s biotechnology industry.

ETF Objective

The Global X China Biotech Innovation ETF (CHB) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index.

Trading Details As of 01/19/22

Ticker CHB
Bloomberg Index Ticker SOLCHB
CUSIP 37954Y251
ISIN US37954Y2515
Primary Exchange Nasdaq
Shares Outstanding 270,000
Number of Holdings 35
30-Day Median Bid-Ask Spread 0.84%

Distributions As of 01/19/22

30-Day SEC Yield -0.22%
Distribution Frequency Semi-Annually

ETF Prices As of 01/19/22

NAV $13.51 Daily Change -$0.35 -2.51%
Market Price $13.50 Daily Change -$0.27 -1.96%

Performance History

As of recent month & quarter-end (12/31/21)
As of recent month & quarter-end (12/31/21)
Fund NAV Market Price Index
1 Year -12.00% -12.71% -11.47%
Since Inception -3.77% -4.24% -3.15%
1 Year -12.00% -12.71% -11.47%
Since Inception -3.77% -4.24% -3.15%
Year-to-Date -12.00% -12.71% -11.47%
1 Month -9.96% -10.58% -9.92%
3 Months -11.35% -11.25% -11.22%
Since Inception -4.77% -5.37% -4.00%
Year-to-Date -12.00% -12.71% -11.47%
1 Month -9.96% -10.58% -9.92%
3 Months -11.35% -11.25% -11.22%
Since Inception -4.77% -5.37% -4.00%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance of the Fund, when observed, is unusual and investors should not expect such performance to be repeated.

Top Holdings As of 01/19/22

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
8.97 300142 C2 WALVAX BIOTECHNOLOGY CO-A BD5CG36 8.39 39,000 327,364.64
8.10 000661 C2 CHANGCHUN HIGH-A BD5CDB3 35.84 8,247 295,602.57
7.46 300601 C2 SHENZHEN KANGT-A BFY8HT2 13.90 19,571 271,999.24
7.01 2269 HK WUXI BIOLOGICS CAYMAN INC BL6B9P1 11.15 22,950 255,829.69
6.16 BGNE BEIGENE LTD-ADR BYYWPW6 236.85 949 224,770.65
5.63 1177 HK SINO BIOPHARMACEUTICAL B00XSF9 0.78 264,900 205,360.70
4.78 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 3.90 44,750 174,321.18
4.75 002007 C2 HUALAN BIOLOGI-A BD5CL19 4.43 39,100 173,338.53
3.57 002252 C2 SHANGHAI RAAS -A BD5CPJ5 1.14 114,400 130,077.80
3.16 300676 C2 BGI GENOMICS CO LTD-A BFY8H58 14.52 7,938 115,273.39
3.15 600161 C1 BEIJING TIAN-A BP3R9J4 4.84 23,757 114,897.71
3.12 002030 C2 DAAN GENE CO LTD-A BD5CKW3 3.25 35,080 113,916.91
3.06 603345 C1 FU JIAN ANJOY-A BMXWM11 23.00 4,851 111,561.23
2.88 002422 C2 SICHUAN KELUN-A BD5CL08 3.12 33,700 105,083.62
2.84 688366 C1 SHANGHAI HAOHA-A BLCD7D5 18.48 5,602 103,547.63
2.66 ZLAB ZAI LAB LTD-ADR BD9GVY0 51.97 1,867 97,027.99
2.63 603392 C1 BEIJING WANTAI-A BMXTWX4 35.59 2,700 96,097.51
2.62 300725 C2 PHARMABLOCK SC-A BFY8HC5 18.10 5,281 95,593.27
2.29 300357 C2 ZHEJIANG WOLWO-A BFY8GY0 8.20 10,200 83,690.82
2.24 603127 C1 JOINN LABORATO-A BK94819 15.52 5,260 81,611.26
2.01 300009 C2 ANHUI ANKE BIO-A BD5C829 1.91 38,280 73,186.43
1.42 300318 C2 BEIJING BOHUI -A BMQBTF8 1.56 33,200 51,814.55
1.35 1530 HK 3SBIO INC BY9D3L9 0.83 59,000 49,222.52
1.14 002038 C2 BEIJING SL -A BD5CJD7 1.71 24,300 41,598.32
0.88 300841 C2 CHENGDU KANGHU-A BMXVCN0 35.83 900 32,245.11
0.88 300639 C2 GUANGDONG HYBR-A BMQBTJ2 5.13 6,242 32,036.72
0.86 000078 C2 SHENZ NEPTUNUS-A BD5CBK8 0.54 58,100 31,475.64
0.81 9966 HK ALPHAMAB ONCOLOGY BL6WGG4 1.70 17,400 29,568.93
0.69 603387 C1 GETEIN BIOTECH INC-A BFB4S90 3.52 7,200 25,331.19
0.69 000710 C2 BERRY GENOMICS CO LTD-A BFFJRH2 3.09 8,155 25,172.13
0.56 6855 HK ASCENTAGE PHARMA BK9PZW2 3.47 5,900 20,446.28
0.48 1873 HK VIVA BIOTECH HOLDINGS BJBL0L5 0.53 33,000 17,450.57
0.41 002880 C2 SHENZHEN WEIGU-A BMTCVX0 5.13 2,880 14,772.37
0.32 9939 HK KINTOR PHARMACEUTICAL LTD BMDWVN6 1.51 7,800 11,773.36
0.30 2126 HK JW CAYMAN THERAP BN4NLR9 1.45 7,600 10,983.74
0.12 CASH 1.00 4,325 4,324.51
Holdings are subject to change.

ETF Characteristics As of 01/19/22

Return on Equity 9.90%
Weighted Avg. Market Cap 12,307 M
2020 2021
Price-to-earnings 418.58 61.39
Price-to-book value 6.24 5.91

Source: AltaVista Research, LLC

ETF Risk Stats As of 01/19/22

Versus Beta
S&P 500 -0.27
MSCI EAFE -0.22
MSCI Emg. Mkts 0.45
Standard Deviation 23.20%

Source: AltaVista Research, LLC

ETF Research

View More Related Research

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares typically do not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.